CN107670019A - A kind of Western medicine compound for treating fatty liver and preparation method thereof - Google Patents

A kind of Western medicine compound for treating fatty liver and preparation method thereof Download PDF

Info

Publication number
CN107670019A
CN107670019A CN201711088909.7A CN201711088909A CN107670019A CN 107670019 A CN107670019 A CN 107670019A CN 201711088909 A CN201711088909 A CN 201711088909A CN 107670019 A CN107670019 A CN 107670019A
Authority
CN
China
Prior art keywords
parts
fatty liver
liver
lovastatin
vitamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201711088909.7A
Other languages
Chinese (zh)
Inventor
莫玉艳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201711088909.7A priority Critical patent/CN107670019A/en
Publication of CN107670019A publication Critical patent/CN107670019A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention belongs to pharmaceutical technology field, specifically discloses a kind of Western medicine compound for treating fatty liver, counts in parts by weight, including following components：58 parts of 20 35 parts of glutathione, 15 30 parts of Lovastatin, 15 30 parts of aliskiren, 0.1 0.5 parts of astaxanthin, 1 1.5 parts of vitamin E, 26 parts of polyethylene glycol, 26 parts of lactose and starch slurry.The drug cure rate of present invention treatment fatty liver is up to 80%, and liver cell can also be protected while lipid metabolism is promoted, promotes liver cell to recover, improve liver function.It is quick in terms of fatty liver is treated, effect is good, few side effects, cost-effective.

Description

A kind of Western medicine compound for treating fatty liver and preparation method thereof
Technical field
The invention belongs to drug field, and in particular to a kind of Western medicine compound for treating fatty liver and preparation method thereof.
Background technology
Fatty liver is that the liver fat as caused by a variety of diseases and the cause of disease becomes, the predominantly wine that epidemiology is investigated Chronic fatty liver caused by essence, obesity etc..Excessive drinking history is clinically whether there is according to patient, fatty liver (FLD) is roughly divided into Alcoholic fatty liver (AFLD) and NASH (NAFLD) or both are simultaneously deposited.AFLD refers to fat caused by long-term alcohol Fat liver.NAFLD refers to caused by addition to alcohol and other clear and definite damage liver factors, including simple fatty liver, fat hepatitis And NASH related liver cirrhosis (NASH).The FLD incidences of disease in China increasingly increase, and FLD just turns into the most common chronic liver disease in China One of, and seriously endanger health of people.At present, the specific medicament for the treatment of fatty liver treatment is lacked on the market.
Glutathione has obvious protection and stable liver plasma membrane, promotes liver cell to recover, improves the effect of liver function.
Lovastatin competitively suppresses the rate-limiting enzyme hydroxyl first glutaryl coenzyme A reductase during cholesterol biosynthesis in vivo Enzyme, the synthesis of cholesterol is reduced, also make LDL receptor synthesis increase, as a result main function position makes in liver Cholesterolemia and low-density lipoprotein cholesterol level are reduced, and by lovastatin tablet, this is prevented atherosclerosis and coronary heart disease Control and act.Lovastatin also reduces serum triglyceride level and increases blood hdl level.Lovastatin with Aliskiren is used in combination, and can effectively reduce the interior fat content of liver.
The content of the invention
In order to solve the above problems, the present invention provides a kind of Western medicine compound for treating fatty liver and preparation method thereof, this Invention treatment fatty liver medicine easily absorb, be quick, effect is good, few side effects, it is cost-effective the advantages that.
The present invention is only applicable to Patients with Fatty Liver, there is other diseases or hepatic and kidney function obstacle person disabling.
The technical scheme that the present invention solves above-mentioned technical problem is as follows：A kind of Western medicine compound for treating fatty liver, by weight Measure number meter, including following components：Glutathione 20-35 parts, Lovastatin 15-30 parts, aliskiren 15-30 parts, astaxanthin 0.1-0.5 parts, vitamin E 1-1.5 parts, polyethylene glycol 2-6 parts, lactose 2-6 parts and starch slurry 5-8 parts.
On the basis of above-mentioned technical proposal, the present invention can also do following improvement.
Preferably, a kind of Western medicine compound for treating fatty liver, is counted in parts by weight, including following components：Glutathione 20 parts, 30 parts of Lovastatin, 30 parts of aliskiren, 0.1 part of astaxanthin, 1.5 parts of vitamin E, 6 parts of polyethylene glycol, 2 parts of lactose With 8 parts of starch slurry.
Preferably, a kind of Western medicine compound for treating fatty liver, is counted in parts by weight, including following components：Glutathione 35 parts, 15 parts of Lovastatin, 15 parts of aliskiren, 0.5 part of astaxanthin, 1 part of vitamin E, 2 parts of polyethylene glycol, 6 parts of lactose and 5 parts of starch slurry.
Preferably, a kind of Western medicine compound for treating fatty liver, is counted in parts by weight, including following components：Glutathione 25 parts, 20 parts of Lovastatin, 20 parts of aliskiren, 0.3 part of astaxanthin, 1.2 parts of vitamin E, 4 parts of polyethylene glycol, 4 parts of lactose With 6 parts of starch slurry.
Preferably, a kind of Western medicine compound for treating fatty liver, is counted in parts by weight, including following components：Glutathione 30 parts, 25 parts of Lovastatin, 25 parts of aliskiren, 0.2 part of astaxanthin, 1 part of vitamin E, 5 parts of polyethylene glycol, 5 parts of lactose and 7 parts of starch slurry.
The present invention also provides a kind of preparation method for the Western medicine compound for treating fatty liver, comprises the following steps：
Step 1：Count in parts by weight, take following raw material：Glutathione 20-35 parts, Lovastatin 15-30 parts, A Like Logical sequence 15-30 parts, astaxanthin 10-35 parts and vitamin E 10-30 parts；
Step 2：Glutathione, Lovastatin, aliskiren, astaxanthin and vitamin are mixed, granulation, obtain medicine of the present invention The active material of compositions；
Step 3：The active material is mixed with polyethylene glycol, lactose, starch slurry, is made according to galenic pharmacy conventional method.
Compared with prior art, the beneficial effects of the invention are as follows：
The medicine of present invention treatment fatty liver is being combined using liver-protective medicine with reducing medicine fatty in liver, While fat content in reducing liver, liver is protected, reduction is taken the side effect that Western medicine pair body is sent, reduced to liver Damage.Therefore, medicine of the invention can also be protected while lipid metabolism is promoted liver cell, promote liver cell recover, Improve liver function；It is quick in terms of fatty liver is treated, effect is good, few side effects, cost-effective.
Embodiment
The principles and features of the present invention are described below, and the given examples are served only to explain the present invention, is not intended to limit Determine the scope of the present invention.
Embodiment 1
A kind of preparation method for the Western medicine compound for treating fatty liver, comprises the following steps：
Step 1：Count in parts by weight, take following raw material：Glutathione 20g, Lovastatin 30g, aliskiren 30g, shrimp Blue or green plain 0.1g, vitamin E 1.5g, polyethylene glycol 6g, lactose 2g and starch slurry 8g；
Step 2：Glutathione, Lovastatin, aliskiren, astaxanthin and vitamin are mixed, granulation, obtain medicine of the present invention The active material of compositions；
Step 3：The active material is mixed with polyethylene glycol, lactose, starch slurry, is made according to galenic pharmacy conventional method.
Embodiment 2
A kind of preparation method for the Western medicine compound for treating fatty liver, comprises the following steps：
Step 1：Count in parts by weight, take following raw material：Glutathione 35g, Lovastatin 15g, aliskiren 15g, shrimp Blue or green plain 0.5g, vitamin E 1g, polyethylene glycol 2g, lactose 6g and starch slurry 5g；
Step 2：Glutathione, Lovastatin, aliskiren, astaxanthin and vitamin are mixed, granulation, obtain medicine of the present invention The active material of compositions；
Step 3：The active material is mixed with polyethylene glycol, lactose, starch slurry, is made according to galenic pharmacy conventional method.
Embodiment 3
A kind of preparation method for the Western medicine compound for treating fatty liver, comprises the following steps：
Step 1：Count in parts by weight, take following raw material：Glutathione 25g, Lovastatin 20g, aliskiren 20g, shrimp Blue or green plain 0.3g, vitamin E 1.2g, polyethylene glycol 4g, lactose 4g and starch slurry 6g；
Step 2：Glutathione, Lovastatin, aliskiren, astaxanthin and vitamin are mixed, granulation, obtain medicine of the present invention The active material of compositions；
Step 3：The active material is mixed with polyethylene glycol, lactose, starch slurry, is made according to galenic pharmacy conventional method.
Embodiment 4
A kind of preparation method for the Western medicine compound for treating fatty liver, comprises the following steps：
Step 1：Count in parts by weight, take following raw material：Glutathione 30g, Lovastatin 25g, aliskiren 25g, shrimp Blue or green plain 0.2g, vitamin E 1g, polyethylene glycol 5g, lactose 5g and starch slurry 7g；
Step 2：Glutathione, Lovastatin, aliskiren, astaxanthin and vitamin are mixed, granulation, obtain medicine of the present invention The active material of compositions；
Step 3：The active material is mixed with polyethylene glycol, lactose, starch slurry, is made according to galenic pharmacy conventional method.
Comparative example
A kind of preparation method for the Western medicine compound for treating fatty liver, comprises the following steps：
Step 1：Count in parts by weight, take following raw material：Glutathione 30g, astaxanthin 0.2g and vitamin E 1g, poly- second Glycol 5g, lactose 5g and starch slurry 7g；
Step 2：By glutathione, astaxanthin, vitamin, mixing, pelletize, obtain the active matter of pharmaceutical composition of the present invention Matter；
Step 3：The active material is mixed with polyethylene glycol, lactose, starch slurry, is made according to galenic pharmacy conventional method.
The test of pesticide effectiveness：
The compound preparation of present invention implementation 1 is used for the clinical test of Patients with Fatty Liver, evaluates the treatment fat of the present embodiment 1 The effect of medicine of fat liver.
1st, case selection：
Choose 200 untreateds or disable other antihypertensive drugs Patients with Fatty Liver of more than two weeks, wherein male patient 98, female patient 102, the oldest is 65 years old, minimum 24 years old, average age 43 years old, and 200 patients are randomly divided into Two groups, experimental group and control group, every group of patient 100.
2nd, instructions of taking：
Experimental group takes the present invention and implements to treat the medicine of fatty liver, twice a day, each 1g, during medication made from 1 Between be 45 days；Control group take in comparative example it is obtained treatment fatty liver medicine, day twice, each 1g, medicine time 45 My god.
3rd, curative effect judges：
Cure：Patient is carried out routine examination, fat drops to normal level in patient's liver, i.e., less than liver mass 5%；
Effectively：Patient is carried out routine examination, fat content declines in patient's liver, but does not drop to normal level；
It is invalid：Patient is carried out routine examination, significant change does not occur for fat content in patient's liver, also without any decline Trend.
4th, test result：
The medicine of 1 treatment fatty liver of this implementation, total effective rate 82%, inefficiency 18%.Specific data are shown in Table 1.
The test result contrast table of table 1
Cure Effectively It is invalid Total effective rate Inefficiency
Experimental group 38 44 18 82% 18%
Control group 22 48 30 70% 30%
The drug cure rate of present invention treatment fatty liver is up to 82%, and liver can also be protected while lipid metabolism is promoted Cell, promote liver cell to recover, improve liver function.It is quick in terms of fatty liver is treated, effect is good, few side effects, cost performance It is high.

Claims (6)

  1. A kind of 1. Western medicine compound for treating fatty liver, it is characterised in that count in parts by weight, including following components：Gluathione It is peptide 20-35 parts, Lovastatin 15-30 parts, aliskiren 15-30 parts, astaxanthin 0.1-0.5 parts, vitamin E 1-1.5 parts, poly- Ethylene glycol 2-6 parts, lactose 2-6 parts and starch slurry 5-8 parts.
  2. A kind of 2. Western medicine compound for treating fatty liver according to claim 1, it is characterised in that count in parts by weight, Including following components：20 parts of glutathione, 30 parts of Lovastatin, 30 parts of aliskiren, 0.1 part of astaxanthin, vitamin E 1.5 Part, 6 parts of polyethylene glycol, 2 parts of lactose and 8 parts of starch slurry.
  3. A kind of 3. Western medicine compound for treating fatty liver according to claim 1, it is characterised in that count in parts by weight, Including following components：35 parts of glutathione, 15 parts of Lovastatin, 15 parts of aliskiren, 0.5 part of astaxanthin, 1 part of vitamin E, 5 parts of 2 parts of polyethylene glycol, 6 parts of lactose and starch slurry.
  4. A kind of 4. Western medicine compound for treating fatty liver according to claim 1, it is characterised in that count in parts by weight, Including following components：25 parts of glutathione, 20 parts of Lovastatin, 20 parts of aliskiren, 0.3 part of astaxanthin, vitamin E 1.2 Part, 4 parts of polyethylene glycol, 4 parts of lactose and 6 parts of starch slurry.
  5. A kind of 5. Western medicine compound for treating fatty liver according to claim 4, it is characterised in that count in parts by weight, Including following components：30 parts of glutathione, 25 parts of Lovastatin, 25 parts of aliskiren, 0.2 part of astaxanthin, 1 part of vitamin E, 7 parts of 5 parts of polyethylene glycol, 5 parts of lactose and starch slurry.
  6. 6. a kind of preparation method for the Western medicine compound for treating fatty liver, it is characterised in that comprise the following steps：
    Step 1：Count in parts by weight, take following raw material：Glutathione 20-35 parts, Lovastatin 15-30 parts, aliskiren 15- 30 parts, astaxanthin 10-35 parts and vitamin E 10-30 parts；
    Step 2：Glutathione, Lovastatin, aliskiren, astaxanthin and vitamin are mixed, granulation, obtain medicine group of the present invention The active material of compound；
    Step 3：The active material is mixed with polyethylene glycol, lactose, starch slurry, is made according to galenic pharmacy conventional method.
CN201711088909.7A 2017-11-08 2017-11-08 A kind of Western medicine compound for treating fatty liver and preparation method thereof Withdrawn CN107670019A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711088909.7A CN107670019A (en) 2017-11-08 2017-11-08 A kind of Western medicine compound for treating fatty liver and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201711088909.7A CN107670019A (en) 2017-11-08 2017-11-08 A kind of Western medicine compound for treating fatty liver and preparation method thereof

Publications (1)

Publication Number Publication Date
CN107670019A true CN107670019A (en) 2018-02-09

Family

ID=61146797

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201711088909.7A Withdrawn CN107670019A (en) 2017-11-08 2017-11-08 A kind of Western medicine compound for treating fatty liver and preparation method thereof

Country Status (1)

Country Link
CN (1) CN107670019A (en)

Similar Documents

Publication Publication Date Title
US11464821B2 (en) Composition for reducing cancer cachexia or weight loss caused by anticancer drug therapy or radiation therapy comprising ginseng extract having increased ginsenoside Rg3 and Rh2
CN109476701B (en) Composition for protecting cells comprising cyclamic acid-proline as active ingredient
WO2012162669A1 (en) Methods of treating multiple sclerosis and preserving and/or increasing myelin content
CN102670864A (en) Medicine composition with antioxidant function for treating cardiovascular and cerebrovascular diseases and sugar diabetes
US11173188B2 (en) Orange peel ferments and preparations and applications thereof
US4477434A (en) Medicinal compositions, foods and beverages having therapeutic effects on diseases of circulatory system and digestive system
CN106389408A (en) Application of polyoxymethylflavone, polyoxymethylflavone composition and polyoxymethylflavone preparation for prevention or treatment of hyperlipidemia
CN101433593A (en) Compound Chinese medicine preparation for treating cardiovascular disease and preparation method thereof
CN107670019A (en) A kind of Western medicine compound for treating fatty liver and preparation method thereof
CN110251591A (en) A kind of pharmaceutical composition and its preparation method and application that aided blood pressure-lowering is hypoglycemic
CN104758451A (en) Traditional Chinese medicine composite for treating gout
CN107648586A (en) A kind of medicine for treating fatty liver and preparation method thereof
EP3914237B1 (en) Olive fruit extract suitable for reducing body-mass index and visceral fat in overweight subjects
CN110368474A (en) A kind of compound Chinese medicinal preparation and preparation method thereof for treating Parkinson's disease dysphagia
CN107669674A (en) A kind of compound preparation of three high drop and preparation method thereof
CN107879961A (en) A kind of composition for treating liver fibrosis
CN107789343A (en) A kind of medicine for treating antimigraine and preparation method thereof
CN107789348A (en) A kind of Western medicine compound for treating high fat of blood and preparation method thereof
CN107693598A (en) A kind of compound preparation of reducing blood lipid and preparation method thereof
CN102526033B (en) Composition prepared from epigallocatechin gallate and mitomycin C and used for suppressing tumor cell proliferation
US20240358726A1 (en) Specific therapeutic medical marijuana doses for stress and pain
CN117679497A (en) Application of lipoprotein lipase in preparation of products for treating non-alcoholic fatty liver disease
CN103386039B (en) Medicine for degrading transaminase and liver virus and preparation method thereof
CN107773558A (en) A kind of medicine of three high drop and preparation method thereof
CN107753658A (en) A kind of pharmaceutical composition for treating fatty liver and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20180209

WW01 Invention patent application withdrawn after publication